Brought to you by 
Alimera, Control Delivery Systems develop DME therapy; later add other indications, amend deal
11 Jul 2017
Executive Summary
Ophthalmic pharmaceuticals start-up Alimera Sciences (founded 2003--developing and in-licensing OTC and prescription eye care treatments) and back-of-eye drug delivery firm Control Delivery Systems will collaborate on the development and marketing of a treatment for diabetic macular edema, a condition that can lead to vision loss in diabetic retinopathy patients.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alimera, Control Delivery Systems develop DME therapy; later add other indications, amend deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice